Ignite Creation Date:
2025-12-25 @ 4:03 AM
Ignite Modification Date:
2025-12-26 @ 2:58 AM
Study NCT ID:
NCT04204902
Status:
COMPLETED
Last Update Posted:
2023-11-08
First Post:
2019-12-17
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib
Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-10-17
Start Date Type:
ACTUAL
Primary Completion Date:
2019-12-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-12-16
Completion Date Type:
ACTUAL
First Submit Date:
2019-12-17
First Submit QC Date:
None
Study First Post Date:
2019-12-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-01-30
Results First Submit QC Date:
None
Results First Post Date:
2023-11-08
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-01-30
Last Update Post Date:
2023-11-08
Last Update Post Date Type:
ACTUAL